These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25686681)

  • 1. Antiretroviral therapy reduces neurodegeneration in HIV infection.
    Bryant AK; Ellis RJ; Umlauf A; Gouaux B; Soontornniyomkij V; Letendre SL; Achim CL; Masliah E; Grant I; Moore DJ
    AIDS; 2015 Jan; 29(3):323-30. PubMed ID: 25686681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment.
    Moore DJ; Masliah E; Rippeth JD; Gonzalez R; Carey CL; Cherner M; Ellis RJ; Achim CL; Marcotte TD; Heaton RK; Grant I;
    AIDS; 2006 Apr; 20(6):879-87. PubMed ID: 16549972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individuals.
    Chow FC; Boscardin WJ; Mills C; Ko N; Carroll C; Price RW; Deeks S; Sorond FA; Hsue PY
    AIDS; 2016 Jan; 30(1):45-55. PubMed ID: 26372478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early viral suppression improves neurocognitive outcomes in HIV-infected children.
    Crowell CS; Huo Y; Tassiopoulos K; Malee KM; Yogev R; Hazra R; Rutstein RM; Nichols SL; Smith RA; Williams PL; Oleske J; Muller WJ;
    AIDS; 2015 Jan; 29(3):295-304. PubMed ID: 25686678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.
    Cross HM; Combrinck MI; Joska JA
    S Afr Med J; 2013 Sep; 103(10):758-62. PubMed ID: 24079630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy.
    Cuzin L; Pugliese P; Sauné K; Allavena C; Ghosn J; Cottalorda J; Rodallec A; Chaix ML; Fafi-Kremer S; Soulié C; Ouka M; Charpentier C; Bocket L; Mirand A; Guiguet M;
    AIDS; 2015 Aug; 29(13):1665-71. PubMed ID: 26372277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
    Metzner KJ; Allers K; Rauch P; Harrer T
    AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens.
    Manavi K; Scott G
    Int J STD AIDS; 2006 Aug; 17(8):522-4. PubMed ID: 16925897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy.
    Montoya JL; Iudicello J; Oppenheim HA; Fazeli PL; Potter M; Ma Q; Mills PJ; Ellis RJ; Grant I; Letendre SL; Moore DJ;
    AIDS; 2017 Mar; 31(6):787-795. PubMed ID: 28099190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered.
    Gelman BB
    Curr HIV/AIDS Rep; 2015 Jun; 12(2):272-9. PubMed ID: 25860316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of deworming on disease progression markers in HIV-1-infected pregnant women on antiretroviral therapy: a longitudinal observational study from Rwanda.
    Ivan E; Crowther NJ; Mutimura E; Rucogoza A; Janssen S; Njunwa KK; Grobusch MP
    Clin Infect Dis; 2015 Jan; 60(1):135-42. PubMed ID: 25210019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.
    Zoufaly A; Kiepe JG; Hertling S; Hüfner A; Degen O; Feldt T; Schmiedel S; Kurowski M; van Lunzen J
    HIV Med; 2014 Sep; 15(8):449-57. PubMed ID: 24580846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
    Scott Sutton S; Magagnoli J; Hardin JW
    Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERP evidence of impaired central nervous system function in virally suppressed HIV patients on antiretroviral therapy.
    Chao LL; Lindgren JA; Flenniken DL; Weiner MW
    Clin Neurophysiol; 2004 Jul; 115(7):1583-91. PubMed ID: 15203059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.
    Cao W; Mehraj V; Trottier B; Baril JG; Leblanc R; Lebouche B; Cox J; Tremblay C; Lu W; Singer J; Li T; Routy JP; ; Vézina S; Charest L; Milne M; Huchet E; Lavoie S; Friedman J; Duchastel M; Villielm F; Côté P; Potter M; Lessard B; Charron MA; Dufresne S; Turgeon ME; Rouleau D; Labrecque L; Fortin C; de Pokomandy A; Hal-Gagné V; Munoz M; Deligne B; Martel-Laferrière V; Gilmore N; Fletcher M; Szabo J
    Clin Infect Dis; 2016 Jan; 62(2):250-257. PubMed ID: 26349551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. White matter micro-structural changes in ART-naive and ART-treated children and adolescents infected with HIV in South Africa.
    Hoare J; Fouche JP; Phillips N; Joska JA; Paul R; Donald KA; Thomas KG; Stein DJ
    AIDS; 2015 Sep; 29(14):1793-801. PubMed ID: 26372385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved retention associated with community-based accompaniment for antiretroviral therapy delivery in rural Rwanda.
    Franke MF; Kaigamba F; Socci AR; Hakizamungu M; Patel A; Bagiruwigize E; Niyigena P; Walker KD; Epino H; Binagwaho A; Mukherjee J; Farmer PE; Rich ML
    Clin Infect Dis; 2013 May; 56(9):1319-26. PubMed ID: 23249611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
    Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
    Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals.
    Kalayjian RC; Robertson KR; Albert JM; Fichtenbaum CJ; Brown TT; Taiwo BO;
    J Acquir Immune Defic Syndr; 2019 Jun; 81(2):e49-e54. PubMed ID: 30939531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.